Linezolid Accord

Linezolid, the active ingredient in Linezolid Accord, is an oxazolidinone presented as a intravenous formulation for intravenous use. It treats Gram‑positive bacterial infections including MRSA, skin and soft‑tissue infections, and community‑acquired or nosocomial pneumonia in adult patients.

GNH USA supplies Linezolid Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Linezolid Accord is indicated for infections caused by Gram‑positive bacteria, targeting the pathways of protein synthesis inhibition. - Skin and soft tissue infections: effective against Staphylococcus aureus and Streptococcus species, reducing infection severity. - Community‑acquired and nosocomial pneumonia: provides bacterial clearance in lung infections caused by susceptible Gram‑positive organisms. - Methicillin‑resistant Staphylococcus aureus (MRSA) infections: achieves bacteriostatic activity against resistant strains.

Adverse reactions may occur with linezolid therapy.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: loose stools, occasionally watery. - Headache: transient cranial discomfort. - Vomiting: occasional emesis. - Rash: mild skin erythema. - Metallic taste: altered taste perception.

Serious or Rare Side Effects: - Thrombocytopenia: significant drop in platelet count. - Anemia: reduced red blood cell levels. - Peripheral neuropathy: nerve pain or sensory changes. - Serotonin syndrome: risk when combined with serotonergic agents. - Lactic acidosis: metabolic disturbance. - Optic neuritis: visual disturbances requiring immediate attention.

Clinicians should consider several safety measures before initiating linezolid therapy. - Renal impairment: monitor renal function and adjust monitoring as linezolid is primarily excreted unchanged. - Hepatic dysfunction: assess liver enzymes regularly. - Concomitant serotonergic agents: avoid due to risk of serotonin syndrome. - Myelosuppression: perform routine complete blood counts. - Hypersensitivity: discontinue immediately if allergic reaction occurs. - Store at ambient temperature: keep in original container, protect from moisture and light.

Linezolid may interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Selective serotonin reuptake inhibitors (SSRIs): risk of serotonin syndrome. - Monoamine oxidase inhibitors (MAOIs): risk of serotonin syndrome. - Rifampicin: reduces linezolid plasma concentrations. - Erythromycin: may increase linezolid levels. - Tyramine‑rich foods: may precipitate hypertensive reactions.

Moderate Interactions (Monitor Closely): - Warfarin: may enhance anticoagulant effect. - Phenytoin: may lower linezolid concentrations. - Cimetidine: may increase linezolid exposure. - Anticonvulsants: monitor for reduced seizure control. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): monitor for bleeding risk.